GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect
Phase 1
Completed
- Conditions
- Muscular Dystrophies
- Interventions
- Drug: GSK3439171ADrug: Placebo
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 66
- Registration Number
- NCT03627494
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Twinrix Pregnancy Registry
Completed
- Conditions
- Hepatitis
- Interventions
- Other: Data Collection
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT03619590
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Phase 3
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1196
- Registration Number
- NCT03621670
- Locations
- π¬π§
GSK Investigational Site, Edinburg, United Kingdom
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT03614728
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance
Not Applicable
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Procedure: Nasal Swab collectionProcedure: Blood sample collectionProcedure: Cord blood sample collectionOther: Infant Diary CardOther: Maternal Diary Card
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4493
- Registration Number
- NCT03614676
- Locations
- πΉπ
GSK Investigational Site, Chiang Mai, Thailand
Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting
Completed
- Conditions
- Asthma
- Interventions
- Drug: Arnuity
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 668
- Registration Number
- NCT03595930
- Locations
- π°π·
GSK Investigational Site, Seoul, Korea, Republic of
Phase I Study of GSK2982772 in Japanese Healthy Male Participants
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 13
- Registration Number
- NCT03590613
- Locations
- π―π΅
GSK Investigational Site, Fukuoka, Japan
Effect of Two Toothpastes on Bacteria in Saliva
Not Applicable
Completed
- Conditions
- Oral Health
- Interventions
- Drug: Zinc-B toothpasteOther: Mineral waterDrug: Zinc-A toothpaste
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03587428
- Locations
- π¬π§
GSK Investigational Site, Weybridge, United Kingdom
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years
Phase 2
Completed
- Conditions
- Meningitis, Meningococcal
- Interventions
- Biological: MenABCWY vaccineBiological: rMenB+OMV NZ (Bexsero) vaccineBiological: MenACWY (Menveo) vaccine
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 520
- Registration Number
- NCT03587207
- Locations
- π¨πΏ
GSK Investigational Site, Hradec Kralove, Czechia
Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT03568942
- Locations
- πΊπΈ
GSK Investigational Site, La Mesa, California, United States
Β© Copyright 2025. All Rights Reserved by MedPath